SVB Wealth’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

SVB Wealth’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,635	Closed	-$414K	–	1096
2022 Q4	$414K	Buy	3,635 +314	+9%	+$26.1K	0.01%	614
2022 Q3	$206K	Buy	+3,321	New	+$232K	﹤0.01%	845
2022 Q2	–	Sell	-2,073	Closed	-$218K	–	874
2022 Q1	$218K	Buy	2,073 +30	+1%	+$2.92K	﹤0.01%	679
2021 Q4	$220K	Sell	2,043 -300	-13%	-$32.7K	﹤0.01%	673
2021 Q3	$257K	Sell	2,343 -52	-2%	-$5.4K	﹤0.01%	835
2021 Q2	$224K	Buy	+2,395	New	+$220K	﹤0.01%	862

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SVB Wealth's HZNP Position: Q1 2023 in Review

SVB Wealth sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 3,635 shares — an estimated $414K sold.

SVB Wealth first reported a position in HZNP in Q2 2021 and held it in 6 quarters. The position peaked at $414K in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

SVB Wealth reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
SVB Wealth sold 3,635 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $414K.
SVB Wealth first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and held it in 6 quarters.
SVB Wealth's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $414K in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on SVB Wealth's 13F filing for Q1 2023, filed 12 May 2023.